ORPHA:693846
Hepatic arteriovenous malformation
Also known as: Arteriovenous malformation of the liver · Congenital hepatic arteriovenous malformation · HAVM
Publications
128
53.4th percentile
Trials
0
Interventional, condition-specific
Researchers
713
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare visceral arteriovenous characterized by direct arterial-to-venous connections within the liver. Patients may be asymptomatic or present with symptoms such as anemia, consumptive coagulopathy, portal hypertension, and may develop complications including congestive heart failure, necrosis of the liver or hydrops fetalis.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
128 matched papers (75 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
128
128 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
128 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
75 in the last 10 years · medium confidence · 53.4th percentile (publications denominator)
Phrase hits: 128 · MeSH hits: 0
Who's working on it?
713
Distinct author names in 128 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Dupuis-Girod S5 papers · 2023
Hospices Civils de Lyon, Centre de Référence pour la maladie de Rendu-Osler, Hôpital Femme-Mère-Enfants, Bron, France. sophie.dupuis-girod@chu-lyon.fr.
Papers in Europe PMC - 02Decullier E3 papers · 2023
Unité de recherche clinique du pole IMER of the Hospices Civils de Lyon, Lyon, France.
Papers in Europe PMC - 03Letarte M3 papers · 2006Papers in Europe PMC
- 04Abdalla SA2 papers · 2006
Cancer Research Program, The Hospital for Sick Children, and Department of Immunology, University of Toronto, Toronto, Canada. mablab@sickkids.ca
Papers in Europe PMC - 05
- 06Clevert DA2 papers · 2020
Department of Radiology, University Hospital LMU, Marchioninistrasse 15, 81377 Munich, Germany.
Papers in Europe PMC - 07Delagrange L2 papers · 2023
Hospices Civils de Lyon, Centre de Référence pour la maladie de Rendu-Osler, Hôpital Femme-Mère-Enfants, Bron, France.
Papers in Europe PMC - 08Dupuis O2 papers · 2023
Hospices Civils de Lyon, Service de Gynécologie-Obstétrique, Hôpital Lyon-Sud, Pierre-Bénite, France.
Papers in Europe PMC - 09Eyries M2 papers · 2021
Assistance Publique-Hôpitaux de Paris, Département de Génétique, GH Pitié-Salpêtrière, Paris, France.
Papers in Europe PMC - 10Faughnan ME2 papers · 2015
Division of Respirology, Department of Medicine and Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 9 September 2026 · last trial check 9 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 11 · after dedupe 11 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 11 · dropped 0 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (11)
- isrctn·ISRCTN24585341·No longer recruiting·Combining maximized ("proximal") brain protection in percutaneous treatment of carotid artery narrowings with stents designed to trap the atherosclerotic plaque: a study of brain injury
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN81927110·No longer recruiting·A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rtPA in the treatment of intracerebral haemorrhage
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN51505768·No longer recruiting·ARTSS-2: A pilot, phase IIb, randomised, multicentre, safety and activity trial of Argatroban in combination with TPA (Alteplase) Stroke Study
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN50142667·No longer recruiting·Minimally invasive surgery plus rt-PA for ICH evacuation
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN04467549·No longer recruiting·Trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in acute myocardial infarction: The TRANSFER-AMI trial
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN15383301·No longer recruiting·Mannitol for stopping or preventing brain swelling (cerebral oedema) after stroke from bleeding in the brain (intracerebral haemorrhage): a feasibility study
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN14785273·No longer recruiting·Thrombin inhibition preoperatively in early breast cancer
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN85562386·No longer recruiting·Prevention of decline in cognition after stroke trial
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN74381875·Stopped·Percutaneous Randomised Infusion of Marrow Aspirate To Improve Ventricular Efficiency
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN83772183·No longer recruiting·ASPirin in Reducing Events in the Elderly
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN78818544·No longer recruiting·Systemic therapy in advanced or metastatic prostate cancer: evaluation of drug efficacy
Uncertain — At least one provider returned uncertain or parent-category.
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hepatic arteriovenous malformation — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hepatic arteriovenous malformation" OR "Arteriovenous malformation of the liver" OR "Congenital hepatic arteriovenous malformation"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hepatic arteriovenous malformation" OR "Arteriovenous malformation of the liver" OR "Arteriovenous malformation of liver" OR "Congenital hepatic arteriovenous malformation"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HAVM
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T02:07:25.422Z
